Platinum
Diamond
Amgen
At Amgen Oncology, our mission to serve patients drives all that we do. That’s why we’re relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. Visit AmgenOncology.com to learn more.
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Eisai
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US
Follow Us
Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.
To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information:
Follow Us
Janssen
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.
Follow Us
Lilly
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.Lilly.com.
Follow Us
Organon
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines.
For more information, visit www.Organon.com and connect with us socially.
Follow Us
Regeneron
Since 2007, Regeneron and Sanofi have collaborated to help people with debilitating and complex conditions that are often difficult to diagnose and treat, using fully-human monoclonal antibodies. Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, rare blood disorders, neurology, immunology and oncology.
© 2022 Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. All rights reserved.
ONC.22.01.0044 2/22
Follow Us
Supporter
AbbVie
At AbbVie, we are committed to transforming standards of care for blood cancers while advancing a dynamic pipeline of investigational therapies across many cancer types. Our dedicated team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines for patients. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the most debilitating cancers. For more details:
Follow Us
Kite
Follow Us
